167 related articles for article (PubMed ID: 2313599)
1. Direct binding and functional studies on muscarinic cholinoceptors in porcine coronary artery.
Yamada S; Yamazawa T; Nakayama K
J Pharmacol Exp Ther; 1990 Feb; 252(2):765-9. PubMed ID: 2313599
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
3. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
4. Characterization of muscarinic receptors of the rabbit ear artery smooth muscle and endothelium.
Hynes MR; Banner W; Yamamura HI; Duckles SP
J Pharmacol Exp Ther; 1986 Jul; 238(1):100-5. PubMed ID: 3755169
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of binding sites on cardiac muscarinic receptors induced by the neuromuscular blocking agents gallamine and pancuronium.
Dunlap J; Brown JH
Mol Pharmacol; 1983 Jul; 24(1):15-22. PubMed ID: 6135150
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic receptor subtypes in human nasal mucosa: characterization, autoradiographic localization, and function in vitro.
Okayama M; Mullol J; Baraniuk JN; Hausfeld JN; Feldman B; Merida M; Shelhamer JH; Kaliner MA
Am J Respir Cell Mol Biol; 1993 Feb; 8(2):176-87. PubMed ID: 8427708
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic receptors of the vascular bed: radioligand binding studies on bovine splenic veins.
Brunner F; Kukovetz WR
J Cardiovasc Pharmacol; 1986; 8(4):712-21. PubMed ID: 2427809
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel receptor sites for (+)-[3H]PN 200-110 in coronary artery.
Yamada S; Kimura R; Harada Y; Nakayama K
J Pharmacol Exp Ther; 1990 Jan; 252(1):327-32. PubMed ID: 2153804
[TBL] [Abstract][Full Text] [Related]
9. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
10. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
11. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic receptor subtype in porcine coronary artery.
Yamada S; Yamazawa T; Harada Y; Yamamura HI; Nakayama K
Eur J Pharmacol; 1988 Jun; 150(3):373-6. PubMed ID: 3416915
[TBL] [Abstract][Full Text] [Related]
13. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic cholinergic ligand binding to intact mouse pituitary tumor cells (AtT-20/D16-16) coupling with two biochemical effectors: adenylate cyclase and phosphatidylinositol turnover.
Akiyama K; Vickroy TW; Watson M; Roeske WR; Reisine TD; Smith TL; Yamamura HI
J Pharmacol Exp Ther; 1986 Mar; 236(3):653-61. PubMed ID: 3005550
[TBL] [Abstract][Full Text] [Related]
15. Muscarinic cholinergic regulation of electrogenic chloride secretion in porcine proximal jejunum.
Chandan R; Megarry BH; O'Grady SM; Seybold VS; Brown DR
J Pharmacol Exp Ther; 1991 May; 257(2):908-17. PubMed ID: 2033527
[TBL] [Abstract][Full Text] [Related]
16. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological differences between the high-affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cismethyldioxolane.
Vickroy TW; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1984 Jun; 229(3):747-55. PubMed ID: 6202869
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic cholinergic receptor sites in cerebral blood vessels.
Estrada C; Krause DN
J Pharmacol Exp Ther; 1982 Apr; 221(1):85-90. PubMed ID: 7062294
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characteristics of muscarinic cholinoreceptors in swine tracheal smooth muscle.
Yang CM; Farley JM; Dwyer TM
J Auton Pharmacol; 1986 Mar; 6(1):15-24. PubMed ID: 3957950
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of antagonist binding to cardiac muscarinic acetylcholine receptors by gallamine and other neuromuscular blocking drugs.
Nedoma J; Tucek S; Danilov AF; Shelkovnikov SA
J Pharmacol Exp Ther; 1986 Jan; 236(1):219-23. PubMed ID: 3941394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
